Problematic points of anticoagulant therapy for atrial fibrillation in certain Russian regions in 2016- 2019: results of a retrospective big data analysis
- 10 June 2024
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (9)
Abstract
Aim. This retrospective analysis of anticoagulant therapy prescription rate in patients with atrial fibrillation (AF) aged ³18 years in certain Russian regions in 20162019 using artificial intelligence technologies. Material and methods. Anonymized data of patients with AF aged ³18 years (n=144431; men, 42,0%; mean age, 68,9±15,7 years; mean CHA 2 DS 2 -VASc score, 3,2±1,8) were extracted from the Webiomed predictive analytics service using continuous sampling from electronic health records in medical facilities of 6 Russian constituent entities (Republic of Bashkortostan, Republic of Buryatia, Republic of Karelia, Republic of Sakha (Yakutia), Perm Krai, Yamalo-Nenets Autonomous Okrug) for 2016-2019 using artificial intelligence technologies. Results. Anticoagulant therapy prescription rate in the total sample was 29,7%. Patients with AF and a high thromboembolism risk received anticoagulants in 34,8% of cases. Anticoagulant therapy was prescribed significantly less frequently to women with AF compared to men. In the subgroup of individuals aged under 75 years, anticoagulant therapy prescription rate with a high thromboembolism risk exceeded the same indicator in the subgroup of individuals aged ³75 years as follows: 41,2% vs 29,6% (p2 DS 2 -VASc scale in the range from 33,2% to 61,9%, in patients aged ³75 years — in the range from 13,0% to 55,5%. We revealed that 23317 (16,1%) patients were prescribed direct oral anticoagulants, of which 9,655 (41,4%) patients initially received warfarin. Conclusion. The study results indicate an unsatisfactory anticoagulant therapy prescription rate in patients with AF and a high thromboembolism risk in certain Russian regions in 2016-2019. Despite its growth with a CHA 2 DS 2 -VASc score increase in the high-risk range, it did not comply with current clinical guidelines This specifies the need for stricter control over the implementation of treatment and diagnostic algorithms and local protocols for managing these patients.Keywords
This publication has 17 references indexed in Scilit:
- Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation, 2024
- Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR studyEuropean Heart Journal, 2023
- 2020 Clinical guidelines for Atrial fibrillation and atrial flutterRussian Journal of Cardiology, 2021
- Central directions for reducing cardiovascular mortality: what can be changed today?Russian Journal of Cardiology, 2020
- Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of AgeThe American Journal of Cardiology, 2019
- A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulationEuropean Heart Journal, 2018
- Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR ® ) PINNACLE RegistryJournal of the American Heart Association, 2017
- Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in DenmarkEuropean Heart Journal, 2017
- 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTSRussian Journal of Cardiology, 2017
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014